UBS Group Trims RAPT Therapeutics (NASDAQ:RAPT) Target Price to $2.00

RAPT Therapeutics (NASDAQ:RAPT) had its price target cut by UBS Group from $10.00 to $2.00 in a research note released on Monday morning, Benzinga reports. The firm currently has a neutral rating on the stock.

RAPT has been the subject of several other reports. HC Wainwright reissued a neutral rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. Wolfe Research reaffirmed a peer perform rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th. Nine investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $20.43.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $1.93 on Monday. RAPT Therapeutics has a one year low of $1.77 and a one year high of $27.35. The firm has a 50 day simple moving average of $2.68 and a 200-day simple moving average of $5.11. The firm has a market cap of $67.36 million, a price-to-earnings ratio of -0.63 and a beta of 0.34.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.03. Equities analysts predict that RAPT Therapeutics will post -2.73 EPS for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its stake in RAPT Therapeutics by 65.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock valued at $59,000 after acquiring an additional 2,621 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in RAPT Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in RAPT Therapeutics during the 4th quarter valued at $233,000. Chesapeake Capital Corp IL acquired a new position in RAPT Therapeutics during the 4th quarter worth about $254,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of RAPT Therapeutics in the first quarter valued at approximately $97,000. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.